Cargando…
Poor Prognosis of Pulmonary Adenosquamous Carcinoma with NRAS and HRAS Double Mutation
RAS mutations constitute one of the major tumorigenic mechanisms and are detected in approximately 20% of lung cancers. The most frequent mutated and well-studied RAS isoform is KRAS, which is associated with an overall poor prognosis in non-small-cell lung cancer (NSCLC). However, the clinical sign...
Autores principales: | Zhao, Jidong, Zhang, Xiangmei, He, Ming, Chen, Xin, Cui, Xing, Qin, Tian, Niu, Xueliang, Zhao, Liyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898223/ https://www.ncbi.nlm.nih.gov/pubmed/33628034 http://dx.doi.org/10.2147/OTT.S295813 |
Ejemplares similares
-
Concomitant deletion of HRAS and NRAS leads to pulmonary immaturity, respiratory failure and neonatal death in mice
por: Fuentes-Mateos, Rocío, et al.
Publicado: (2019) -
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
por: Kompier, Lucie C., et al.
Publicado: (2010) -
Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies
por: Siebenaler, Ronald F, et al.
Publicado: (2022) -
Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia
por: Wang, Shujuan, et al.
Publicado: (2020) -
Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital
por: Harahap, Agnes Stephanie, et al.
Publicado: (2023)